REGENXBIO Launches Option Exchange to Re-incentivize Employees and Reduce Dilution

summarizeSummary

REGENXBIO launched an option exchange program for non-executive employees to re-incentivize them with new, lower-strike options, which also reduces potential future share dilution by 2.4%.

check_boxKey Events · Corporate Governance and Compliance · RGNX

• Option Exchange Program Launched

  REGENXBIO is offering non-executive employees the opportunity to exchange 'underwater' stock options (exercise price >= $18.00) for new replacement options. This program aims to re-incentivize employees and improve retention.

• Reduces Potential Dilution

  If all eligible options are exchanged, the program is estimated to reduce the net overhang of outstanding options by 14.0% and the fully diluted share count by 2.4% (from 67,829,507 shares), mitigating future dilution for shareholders.

• New Options with Reset Exercise Price and Vesting

  Replacement options will have an exercise price equal to the closing price of the common stock on the grant date (expected July 2, 2026) and will vest 50% after one year and the remaining 50% after two years. All new options will be non-qualified stock options.

• Shareholder Approval Secured

  The option exchange program was approved by shareholders at the annual meeting held on May 29, 2026, demonstrating investor support for the initiative.

auto_awesomeAnalysis · RGNX · Life Sciences

REGENXBIO has initiated an option exchange program to re-incentivize non-executive employees whose stock options are significantly 'underwater' (exercise price higher than current stock price). This move is critical for retaining talent, especially following recent positive Phase III results for its Duchenne gene therapy, RGX-202, and prior 'going concern' doubts. The program allows eligible employees to exchange existing options for new ones with a market-based exercise price and a new two-year vesting schedule. Importantly, this exchange is projected to result in a net reduction of 2.4% in the company's fully diluted share count, which is a positive for existing shareholders by mitigating future dilution.